U.S. markets open in 5 hours 27 minutes
  • S&P Futures

    3,853.75
    +34.50 (+0.90%)
     
  • Dow Futures

    31,962.00
    +186.00 (+0.59%)
     
  • Nasdaq Futures

    12,500.50
    +203.25 (+1.65%)
     
  • Russell 2000 Futures

    2,225.20
    +24.40 (+1.11%)
     
  • Crude Oil

    65.44
    +0.39 (+0.60%)
     
  • Gold

    1,698.40
    +20.40 (+1.22%)
     
  • Silver

    25.77
    +0.51 (+2.00%)
     
  • EUR/USD

    1.1899
    +0.0047 (+0.39%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.89
    +0.23 (+0.93%)
     
  • GBP/USD

    1.3889
    +0.0067 (+0.49%)
     
  • USD/JPY

    108.6020
    -0.2990 (-0.27%)
     
  • BTC-USD

    54,076.00
    +4,219.45 (+8.46%)
     
  • CMC Crypto 200

    1,090.14
    +65.94 (+6.44%)
     
  • FTSE 100

    6,724.13
    +5.00 (+0.07%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Twist Bioscience Announces Pricing of a $300 Million Upsized Public Offering of Common Stock

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 2,802,272 shares of its common stock at a price to the public of $110.00 per share, which consists of 2,727,272 shares to be sold by Twist and 75,000 shares to be sold by certain selling stockholders. The gross proceeds of the offering to Twist before deducting the underwriting discount and commissions and estimated offering expenses, and assuming no exercise of the underwriters’ option to purchase additional shares from the Company, are expected to be approximately $300 million. Twist has granted the underwriters a 30-day option to purchase up to an additional 409,090 shares of common stock at the public offering price, less the underwriting discount and commissions. The offering is expected to close on or about December 7, 2020, subject to the satisfaction of customary closing conditions. Twist will not receive any proceeds from the sale of common stock by the selling stockholders.

Twist intends to use the net proceeds to be received by it in the offering, along with its existing cash, cash equivalents and short-term investments to increase its operational capacity, tooling, and scaling an additional manufacturing location to support its growth in NGS, synbio, DNA prep, its pharmaceutical biologics antibody platform and IgG products; increase its investment in automation and research and development, which includes investing in NGS, synbio, its pharmaceutical biologics antibody platform, and in DNA data storage; increase its investment in its commercial organization and its IT infrastructure; and for the remainder to fund working capital and general corporate purposes. Twist may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. are acting as joint book-running managers. Robert W. Baird & Co. Incorporated is acting as lead manager.

The securities described above are being offered by Twist and the selling stockholders pursuant to an automatic shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (the "SEC") on June 3, 2020. The offering will be made only by means of a written prospectus and a prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by request from J.P. Morgan Securities LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com, or from Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attn: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com, or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926, or from Evercore Group L.L.C. c/o Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer, solicitation, or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation statements regarding expected net proceeds to be received by Twist in the offering, expected use of proceeds by Twist, and the timing of the closing of the offering, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 27, 2020, the preliminary prospectus supplement related to the public offering and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Twist Bioscience’s results of operations, which would, in turn, have a significant and adverse impact on Twist Bioscience’s stock price. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202006024/en/

Contacts

Twist Media Contact:
Angela Bitting
925- 202-6211
media@twistbioscience.com

Twist Investor Contact:
Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com